- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05417906
Using the Blood Eosinophil Count to Guide Systemic Corticosteroid Treatment in Asthma Exacerbations
Investigating the Blood Eosinophil Count as a Biomarker to Guide Systemic Corticosteroid Treatment in Hospitalized Exacerbations of Asthma: a Randomized, Controlled, Open-label, Noninferiority Trial
Asthma attacks which are moderate-to-severe are typically treated with corticosteroids, but the optimal treatment duration is unknown and treatment responses can be variable. Inadequate treatment may compromise recovery, but increased exposure to corticosteroids is, in turn, associated with drug-related adverse effects.
There is a need for a biomarker to guide duration of corticosteroid treatment in asthma attacks. One such candidate biomarker is the blood eosinophil count, which may predict steroid-responsiveness. We hypothesize that the blood eosinophil count can potentially be used as a biomarker to guide the duration of corticosteroids in moderate-to-severe asthma attacks.
This study will recruit individuals hospitalized for asthma attack. Participants will be randomized to standard care or blood-eosinophil guided systemic corticosteroid therapy. Subjects in the standard arm will receive oral corticosteroids for a total of 5 days. Subjects in the blood-eosinophil guided arm will receive oral corticosteroids for a total of 5 days if admission eosinophil count is ≥ 0.300 x 10^3/µL, and receive 3 days of oral corticosteroids if the admission blood eosinophil is < 0.300 x 10^3/µL. The rate of treatment failure will be compared between these two groups.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Kaori Miranda
- Phone Number: +65 8282 5761
- Email: kaori_miranda@cgh.com.sg
Study Contact Backup
- Name: Siti Norashikin binte Fuad
- Phone Number: +65 8044 1939
- Email: siti_norashikin_fuad@cgh.com.sg
Study Locations
-
-
-
Singapore, Singapore, 168753
- Recruiting
- Singapore General Hospital
-
Contact:
- Mervyn Ong
- Phone Number: +65 9188 4923
- Email: mervyn.ong.h.p@sgh.com.sg
-
Principal Investigator:
- Mariko S Koh, MBBS
-
Sub-Investigator:
- Si Yuan Chew, MBBS
-
Sub-Investigator:
- Ken CH Lee, MBBS
-
Sub-Investigator:
- Pei yee Tiew, MBBS
-
Singapore, Singapore, 529889
- Recruiting
- Changi General Hospital
-
Contact:
- Kaori Miranda
- Phone Number: +65 8282 5761
- Email: kaori_miranda@cgh.com.sg
-
Contact:
- Siti Norashikin binte Fuad
- Phone Number: +65 8044 1939
- Email: siti_norashikin_fuad@cgh.com.sg
-
Principal Investigator:
- Anthony Yii, MB BChir
-
Sub-Investigator:
- Nicole Sieow, MBBS
-
Sub-Investigator:
- Tunn Ren Tay, MBBS
-
Sub-Investigator:
- Xue Ning Choo, MBBS
-
Sub-Investigator:
- Augustine Tee, MBBS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 21 years old
- Admitted for acute exacerbation of asthma and have received ≤ 3 days of systemic corticosteroids
- Have a had a blood eosinophil count (as part of routine clinical care) drawn before administration of systemic corticosteroid
- Have not taken SCS within 7 days prior to presentation to hospital
Exclusion Criteria:
- Concomitant pneumonia
- Admission to high-dependency/intensive care unit, or requirement for invasive/noninvasive mechanical ventilation
- Eosinophilia due to other known causes (eosinophilic granulomatosis and polyangiitis, parasitic infections, malignancy)
- Other concomitant respiratory conditions e.g. chronic obstructive pulmonary disease, bronchiectasis
- Those on anti-IL5 or anti-IL5R treatment
- Pregnant subjects
- Subjects who are already on an investigational drug or has been participating in another clinical study with an investigational product within the last 6 months
- Subjects deemed by investigators to have a life expectancy of < 12 months (any cause)
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard care
|
Oral prednisolone for 5 days
|
Experimental: Eosinophil-directed care
|
Oral prednisolone for 5 days if eosinophil count is ≥ 0.300 x 10^3/µL, or 3 days if eosinophil is < 0.300 x 10^3/µL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants experiencing treatment failure
Time Frame: Through the duration of the index admission for asthma attack, typically 3-5 days
|
Defined as death from any cause, or need for invasive/noninvasive mechanical ventilation, or need to restart/extend systemic steroid treatment
|
Through the duration of the index admission for asthma attack, typically 3-5 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Length of hospital stay (number of days)
Time Frame: Through the duration of the index admission for asthma attack, typically 3-5 days
|
Through the duration of the index admission for asthma attack, typically 3-5 days
|
Cumulative steroid dose at index admission (mg prednisolone-equivalent)
Time Frame: Through the duration of the index admission for asthma attack, typically 3-5 days
|
Through the duration of the index admission for asthma attack, typically 3-5 days
|
Proportion of participants receiving additional systemic steroid course within 14 days
Time Frame: 14 days
|
14 days
|
Asthma Control Questionnaire-5
Time Frame: At baseline, 7, 14, 30 and 90 days
|
At baseline, 7, 14, 30 and 90 days
|
Proportion of participants experiencing all-cause death
Time Frame: 30 and 90 days
|
30 and 90 days
|
Proportion of participants who develop pneumonia
Time Frame: 30 and 90 days
|
30 and 90 days
|
Proportion of participants who develop venous thromboembolism
Time Frame: 30 and 90 days
|
30 and 90 days
|
Proportion of participants who develop sepsis
Time Frame: 30 and 90 days
|
30 and 90 days
|
Proportion of participants who develop fractures
Time Frame: 30 and 90 days
|
30 and 90 days
|
Proportion of participants who develop upper gastrointestinal bleeds/peptic or gastric ulcers
Time Frame: 30 and 90 days
|
30 and 90 days
|
Time to next emergency department visit or admission for asthma
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anthony Yii, MB BChir, Changi General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 03/FY2021/P2/10-A91
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Standard care
-
Evandro Chagas Institute of Clinical ResearchAlejandro Marcel Hasslocher Moreno, MD MSc PhD student; Andrea Costa, MD PhD; Andrea Silvestre de Sousa, MD PhD and other collaboratorsUnknownChagas Heart DiseaseBrazil
-
Neuroscience Trials AustraliaNational Institute for Health Research, United Kingdom; Northern Ireland Chest... and other collaboratorsCompleted
-
University of OklahomaNational Cancer Institute (NCI)CompletedSmoking CessationUnited States
-
Avita MedicalNAMSACompletedVenous Leg UlcersUnited Kingdom, France
-
University of MichiganCompleted
-
University of OklahomaCompletedTobacco Cessation | Tobacco Use | Tobacco Smoking | Smoking Cessation Financial Incentives | Socioeconomic Status | Contingency ManagementUnited States
-
University of OklahomaEnrolling by invitationTobacco Cessation | Tobacco Use | Tobacco Smoking | Smoking Cessation Financial Incentives | Socioeconomic Status | Contingency Management | PregnancyUnited States
-
Institut de Cancérologie de LorraineTerminatedBreast CancerFrance
-
Indonesia UniversityCompletedCovid19 | AcupunctureIndonesia
-
brett rasmussenCompleted